MUSCONE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C16H30O
Molecular Weight	238.4088
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@@H]1CCCCCCCCCCCCC(=O)C1

InChI

InChIKey=ALHUZKCOMYUFRB-OAHLLOKOSA-N

InChI=1S/C16H30O/c1-15-12-10-8-6-4-2-3-5-7-9-11-13-16(17)14-15/h15H,2-14H2,1H3/t15-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C16H30O
Molecular Weight	238.4088
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19763723 | https://www.ncbi.nlm.nih.gov/pubmed/15339420 | https://www.ncbi.nlm.nih.gov/pubmed/22978231

Muscone is the key flavor component of musk that is one of the most popular natural perfumes. Muscone is a promising agent for treating intervertebral disc degeneration through its anti-inflammatory effects. Musk distributing into the brain through blood brain barrier provides the basis for its effect in treating brain disorders. Muscone may be a small active molecule with neuroprotective properties, and that inhibition of apoptosis and Fas is an important mechanism of neuroprotection by muscone. These findings suggest a potential therapeutic role for muscone in the treatment of stroke. Muscone has a protective effect against ischemia-reperfusion injury in cardiac myocytes, indicating that muscone may potentially provide therapeutic benefit in ischemia-reperfusion injury by inhibiting cellular oxidative stress and apoptosis.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Apoptosis 155 Target ID: WP254 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21856397	Inhibitor 8297
Oxidative Stress 160 Target ID: WP408 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21856397	Inhibitor 8297
Fas signaling pathway 1 Target ID: GO:0036337 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22978231	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
Intervertebral disc degradation 4 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19763723	Primary	Preclinical	Unknown Approved Use Unknown
Myocardial infarction 121 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21856397	Primary	Basic research	Unknown Approved Use Unknown
Stroke 144 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22978231	Primary	Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
[Syntheses of macrocyclic products with a musky odor; new synthesis of muscone].	1947 Dec 1	18897227

Patents

Sample Use Guides

In Vivo Use Guide

150 mg/kg for 3 days

Route of Administration: Intraperitoneal

In Vitro Use Guide

In end-plate chondrocytes, exogenous IL-1b resulted in an increase of endogenous IL-1b, TNF-a, and COX-2 mRNA expression, but treatment with 25 uM/L muscone reduced the three cytokines induced by exogenous IL-1b. In end-plate chondrocytes, nitrite levels were induced by IL-1b. The response was attenuated by muscone in a dose-dependent manner, especially by 25 uM/L muscone.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 08:33:28 GMT 2023` Edited by `admin` on `Sat Dec 16 08:33:28 GMT 2023`
Record UNII	UPS3C6CV36
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MUSCONE

Official Name

English

MUSCONE [INCI]

Common Name

English

(-)-3-METHYLCYCLOPENTADECANONE

Systematic Name

English

MUSCONE [MI]

Common Name

English

CYCLOPENTADECANONE, 3-METHYL-, (3R)-

Systematic Name

English

(-)-(3R)-3-METHYLCYCLOPENTADECANONE

Systematic Name

English

Code System Code Type Description

FDA UNII

UPS3C6CV36